Participated · Seed · Sep 2025

Immuto Scientific is developing an AI-powered structural surfaceomics platform that integrates high-resolution proteomics, live-cell protein structural assessment, and advanced analytics to uncover novel, disease-specific surface protein conformations. By mapping these previously invisible epitopes, the company aims to generate highly selective drug targets, initially focusing on oncology but with plans to expand into immunology and inflammation. Immuto’s approach promises improved therapeutic indices by minimizing overlap with healthy tissue, thereby reducing toxicity. The platform has already identified targets across multiple tumor types, and the company is advancing its lead oncology program through in-vivo studies with the goal of entering IND-enabling work. In addition to building its internal pipeline, Immuto collaborates with pharmaceutical partners; its first partnership with Daiichi Sankyo will co-discover solid-tumor targets and develop antibodies against them. Backed by recent financing, the company will scale its discovery efforts and deepen its data-driven engine to fuel future therapeutics. No revenue or user metrics were disclosed in the articles.

Participated · Series A · Aug 2025

Streamline AI provides an AI-powered platform that automates intake, triage, and matter management for busy in-house legal teams. The platform extracts and structures information from incoming emails and includes a conversational AI assistant to handle routine questions that would otherwise consume attorney time. The company is led by Kathy Zhu and Julian Wimbush and is based in Burlingame, CA. Streamline AI intends to use the new funds to accelerate market expansion to meet surging demand from mid-market and enterprise legal departments struggling with manual processes and resource constraints. The Series A brings the company’s total funding to $14M. The product focus and go-to-market plan target legal departments seeking to reduce manual work and improve efficiency. Streamline AI is an AI-powered, no-code intelligent intake platform that delivers visibility and metrics across G&A business units, starting with legal teams. Led by co-founder and CEO Kathy Zhu—who built DoorDash’s commercial legal and legal operations functions—the company launched with a $3.0M seed round in November 2022. The platform automates high-volume request workflows, learns in the background to improve processes, and tailors intake by business function (for example, non-technical teams versus engineering and product). It addresses legal-specific needs around confidentiality, data permissions, control, and measurement without requiring engineering effort. Customers include Branch Metrics, VSCO, a publicly traded fintech, and an $8.7B computer peripherals company. Streamline AI aims to reduce manual work, lower escalations, and increase the bottom line across companies by giving legal and G&A teams better tools and metrics.

Participated · Seed · Mar 2025

Nimblemind.ai provides an AI-powered data infrastructure platform that curates and labels clinical datasets so healthcare providers can transform unstructured patient data into structured, AI-ready formats. The company’s proprietary approach ingests data from EMRs, patient surveys, and wearable devices and enables clinicians to generate decision-support insights and predictive analytics while preserving data sovereignty and compliance. Nimblemind.ai has secured partnerships with multiple healthcare organizations in the US and Asia to pilot and deploy its platform. With $2.5M in new funding, the company plans to expand specialty-specific AI models, enhance platform capabilities, and onboard more providers seeking AI-enabled care improvements. Leadership frames the product as foundational infrastructure to unlock AI’s potential in healthcare and create non-clinical revenue opportunities for providers.

Participated · Seed · Aug 2024

Fleet offers a cloud-based commuter benefits management platform that integrates with HR, accounting, and finance systems to help employers comply with city and state pre-tax commute mandates while giving employees an easy way to manage transit incentives. The product automates commute analysis, program configuration, invoicing, and payments, enabling auto-deducts, employer subsidies, corporate discounts, and tax benefits. According to the company, customers experience a 3× faster employee adoption rate, a 70% drop in support inquiries, and 50% cost savings versus legacy solutions. Fleet positions its offering as a tool for talent attraction and retention as hybrid work and return-to-office policies complicate commuting. The platform also delivers granular emissions-reduction data, aligning corporate benefit programs with sustainability goals. Backed by $5 million in total venture funding, Fleet plans to use its new capital to enhance and roll out its commuter benefits platform to more U.S. employers, especially in jurisdictions with commuter benefit mandates. Headquartered in San Francisco, the company is supported by experienced HR and fintech angels, including former executives from Robinhood and Brex.

Participated · Series A · Aug 2024

Amulet builds portable sensors that provide rapid, on-site molecular detection for food allergens, toxins, and other environmental contaminants through a consumer wearable (Allergy Amulet) and a commercial detection platform (Amulet Scientific). The company plans to scale its team, expand its detection portfolio, and execute a full product launch to serve a growing waitlist. Since its 2020 seed round, Amulet has secured grant funding from the National Institutes of Health and the U.S. Department of Agriculture. Recent strategic hires include Michelle Wu (Head of Product) and Barkley Jenny (VP of Product) to support commercialization and product development. Amulet also recently became a benefit corporation, reflecting its mission-driven approach to improving food safety for individuals and businesses. The technology targets both consumer needs (people managing food allergies and intolerances) and commercial customers (restaurants, suppliers, and manufacturers) to reduce allergen exposure, contamination-related recalls, and associated health impacts. Allergy Amulet builds a consumer food-allergen detection platform centered on a thumb-sized reader (the "Amulet") paired with a disposable sampler. The device pairs molecularly imprinted polymer (MIP) technology with an electrochemical system to detect common allergenic ingredients in seconds. Its sleek, portable design supports everyday carry (keychain, necklace, wristband) and an optional mobile app to store and share results. Allergy Amulet closed additional Seed funding that brought the round to $4.1 million and previously raised an initial Seed led by a joint venture between Microsoft and the Green Bay Packers. The new capital will be used to accelerate manufacturing, expand product offerings to cover more allergens, grow the team, and educate consumers. The company positions the Amulet as an additional tool for individuals, parents, and businesses to better manage food allergies and reduce reliance on strict avoidance and emergency treatment. Allergy Amulet has developed a small, fast consumer food allergen sensor consisting of a USB-sized reader and disposable test strips housing proprietary sensor chips. The patented, portable technology is designed to fit on a keychain, necklace, wristband, or in a pocket and the company’s case also accommodates epinephrine and antihistamines. The company holds one issued U.S. patent with multiple applications and reports a waitlist with thousands of individuals signed up for an early beta release. Allergy Amulet plans to use new funding to manufacture beta units, launch pre-orders, expand product offerings to cover more allergens, grow its team, add additional restaurant and company partners, and educate consumers about food allergen management tools. The company is led by Co-founder and CEO Abigail Barnes and Co-founder and Scientific Advisor Dr. Joseph BelBruno. Pre-sales were slated for Fall 2020 with a broader launch planned for Fall 2021. Allergy Amulet develops a rapid, portable, point-of-consumption food allergen detection device that connects to a patent-pending disposable test strip. The device enables mobile measurements to help individuals avoid ingesting target allergens. It can be configured as a wearable (for example, a necklace) or integrated into everyday products (for example, an EpiPen). Led by CEO Abigail Barnes and based in Madison, WI, the company plans to begin beta testing of its prototype. Allergy Amulet raised $1.1M in seed funding to grow the team and accelerate product development. Investors in the round include Colle Capital, Bulldog Innovation Group, Foley Ventures, Gopher Angels, Mendota Venture Capital and the Wisconsin Medical Society Foundation.